Previous close | 1.7600 |
Open | 1.7600 |
Bid | 1.7900 x 100 |
Ask | 1.9000 x 100 |
Day's range | 1.6900 - 1.8500 |
52-week range | 1.6200 - 5.7000 |
Volume | |
Avg. volume | 347,416 |
Market cap | 126.199M |
Beta (5Y monthly) | -0.24 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: The Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024 at 11:00 am ET Location: New York, NY A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com. H.C. Wainwright 2nd Annual BioConnect Investor C
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of May 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 31,750 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 47,625 shares of Vor Bio’s common stock to six newly hired employees. The foregoing stock op
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines, bringing a wealth of industry experience and expertise to Vor Bio's Board. In his role at Blueprint Medicines, Dr. Namouni has demonstrated exceptional leadership in building the company's fully in